Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Viracta, a US-based developer of treatments for virus-associated malignancies that counts pharmaceutical company Salubris as an investor, completed a series D round of undisclosed size led by venture capital firm Taiwania Capital Management on Monday. Salubris joined NantKwest, Virtus Inspire Ventures, Latterell Venture Partners and Forward Ventures for a round that closed at $10.7m in…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.